Research analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Trading Down 1.4 %
Shares of PULM stock opened at $2.09 on Tuesday. The firm has a fifty day moving average price of $1.84 and a 200 day moving average price of $1.88. The company has a market cap of $7.63 million, a P/E ratio of -0.54 and a beta of 0.92. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $3.14.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) EPS for the quarter. The firm had revenue of $2.20 million for the quarter. Pulmatrix had a negative return on equity of 63.94% and a negative net margin of 193.49%.
Hedge Funds Weigh In On Pulmatrix
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Recommended Stories
- Five stocks we like better than Pulmatrix
- How to buy stock: A step-by-step guide for beginners
- United Airlines Soars on Earnings Beat
- Consumer Staples Stocks, Explained
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Learn Technical Analysis Skills to Master the Stock Market
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.